Trial Profile
A Randomized Phase II Trial Evaluating The Addition Of Nimotuzumab To Chemoradiation For Patients With Esophageal Squamous Cell Carcinoma After Radical Esophagectomy Who Suffer With Lymph Nodes Recurrence
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Antineoplastics
- Indications Oesophageal cancer
- Focus Therapeutic Use
- 30 Jul 2011 New trial record